|
Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma. |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Loxo; Sunesis Pharmaceuticals; Syndax |
|
Consulting or Advisory Role - Celgene |
Speakers' Bureau - Celgene |
|
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Sanofi; Takeda; Tecnofarma; TG Therapeutics |
Research Funding - Abbvie/Genentech (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Fortis (Inst); Janssen (Inst); Merck (Inst); Sutro Biopharma (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Sanofi; Takeda |
|
|
Employment - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Travel, Accommodations, Expenses - GlaxoSmithKline |
|
|
No Relationships to Disclose |
|
|
|
Other Relationship - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline; Pfizer |
Stock and Other Ownership Interests - GlaxoSmithKline; Pfizer |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - CytomX Therapeutics; CytomX Therapeutics |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Research Funding - Celgene (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst) |